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Abstract: Nitric oxide (NO) is an important signaling molecule and a component of the inflammatory cascade.
Besides, it is also involved in tumorigenesis. Aberrant upregulation and activation of the ERK cascade by NO often
leads to tumor cell development. However, the role of ERK inactivation induced by the negative regulation of NO
during apoptosis is not completely understood. In this study, treatment of A549 and PC9 human lung adenocarcinoma cell lines with cordycepin led to a reduction in their viability. Analysis of the effect of cordycepin treatment
on ERK/Slug signaling activity in the A549 cell line revealed that LPS-induced inflammatory microenvironments
could stimulate the expression of TNF-α, CCL5, IL-1β, IL-6, IL-8 and upregulate NO, phospho-ERK (p-ERK), and Slug
expression. In addition, constitutive expression of NO was observed. Cordycepin inhibited LPS-induced stimulation
of iNOS, NO, p-ERK, and Slug expression. L-NAME, an inhibitor of NOS, inhibited p-ERK and Slug expression. It was
also found that cordycepin-mediated inhibition of ERK downregulated Slug, whereas overexpression of ERK led to
an upregulation of Slug levels in the cordycepin-treated A549 cells. Inhibition of Slug by siRNA induced Bax and
caspase-3, leading to cordycepin-induced apoptosis. Cordycepin-mediated inhibition of ERK led to a reduction in
phospho-GSK3β (p-GSK3β) and Slug levels, whereas LiCl, an inhibitor of GSK3β, upregulated p-GSK3β and Slug.
Overall, the results obtained indicate that cordycepin inhibits the ERK/Slug signaling pathway through the activation
of GSK3β which, in turn, upregulates Bax, leading to apoptosis of the lung cancer cells.
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Introduction
Nitric oxide (NO) is a ubiquitous, water soluble,
free radical gas, playing a central role in a number of physiological as well as pathological processes. Over the past few decades, NO has
been shown as a biologically important molecule in carcinogenesis and tumor growth related studies. It modulates different cancer-related events, such as apoptosis, neovascularization of tumors, invasion, metastasis and survival. In some cases, NO or nitric oxide synthase
(NOS) levels correlate with tumor growth inhibition and in the others, they are related to tumor
cell proliferation, invasion and metastasis [1-3].
Some studies have examined the correlation
between inducible NOS (iNOS) and cancer pro-

gression and demonstrated an induction of inflammatory response [3]. Lipopolysaccharide
(LPS) is known to stimulate immune cells in
the tumor microenvironment to generate proinflammatory cytokines [4].
Extracellular signal-regulated kinase (ERK) is
associated with cancers in humans and plays
a crucial role in gene expression, differentiation, proliferation, cell survival, and apoptosis.
MEK is a MAPKK (Mitogen-activated protein
kinase kinase) that activates MAPK (ERK). The
seven human MEKs are involved in four signaling pathways, namely ERK1/2 (MEK1/2),
p38 (MEK3/6 and sometimes MEK4), c-Jun
N-terminal kinases (JNK) (MEK4/7), and ERK5
(MEK5). The only substrates known so far for
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MEK1 and MEK2 are ERK1 and ERK2, respectively. The ERK signaling pathway is a major
determinant in controlling diverse cellular processes such as growth, survival, apoptosis, differentiation, and migration [4-7].
Snail family transcriptional repressor 2 (Slug)
protein, belonging to the highly conserved
Slug/Snail family, is a zinc finger transcriptional
repressor. The Slug/Snail protein family is present in a number of species, ranging from C.
elegans to humans. The protein is upregulated
during metastatic lung cancer, breast cancer,
and mesothelioma. Recent studies strongly
suggest that Slug acts as a potent inducer of
cell survival and movement. Besides, suppression of Slug was also found to induce apoptosis [8-12].
Cordycepin (3’-deoxyadenosine), the major bioactive component of Cordyceps militaris, has a
wide range of biological effects, such as the
regulation of immunomodulatory, anti-inflammatory, antibacterial, and antitumor effects.
The primary pharmacological activity of Cordyceps militaris extracts depends on the main
ingredients of the extract. Moreover, cordycepin has been shown to exert a large variety
of anti-tumor effects. Some studies have demonstrated that cordycepin induces apoptotic
effect through the regulation of MAPK/ERK and
Slug signaling pathways [13-15].
In this study, LPS-mediated simulation of inflammatory microenvironment was carried out
in vitro, which led to increased expression of
NO in the lung cancer cell line, A549. This was
followed by elucidation of the functional mechanisms underlying the stimulation of ERK/
Slug signaling pathway by NO in lung cancer
cell lines. Cordycepin prevented the NO-mediated constitutive activation of ERK and Slug
transcription factors through the stimulation
of GSK3β. It was also established that the
consequent activation of the Bax/caspase-3/
PARP-pathway leads to cancer cell death.
Materials and methods
Reagents and chemicals
Fetal bovine serum (FBS), 1% (w/v) penicillinstreptomycin, and phosphate-buffered saline
(PBS) were procured from Thermo Fischer ScientificTM (Paisley, Scotland, UK). Dulbecco’s Modified Eagle’s Medium (DMEM), L-NG-nitroarginine methyl ester (L-NAME), LiCl (CAS Number
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7447-41-8, 203637 ALDRICH), and LPS (Lipopolysaccharides, L5418) were purchased from
Sigma-AldrichTM (St. Louis, MO, USA). Cordycepin (3’-Deoxyadenosine from Cordyceps militaris) was procured from R&D system (R&D
Systems, Minneapolis, MN). Annexin-V-FLUOS
staining kit was purchased from two different
sources, namely Roche Diagnostics GmbH
(Mannheim, Germany) and Sigma Chemical
Co. Whole cell lysis buffer was procured from
iNtRONTM Biotechnology Inc. (Seoul, Korea). The
transfection reagent Hilymax and the cellcounting kit-8 were purchased from Dojindo
(Dojindo, Japan). Antibodies against phosphorylated ERK (p-ERK), B cell lymphoma-2 (Bcl2), caspase 3, poly ADP ribose polymerase
(PARP-1), GSK3β, p-GSK3β and β-actin were
obtained from Cell Signaling (Beverly, MA,
USA). Antibodies against ERK, Slug and Bax
were procured from Santa Cruz Biotechnology (Dallas, TX, USA).
Cell lines and cell viability assay
The human lung adenocarcinoma cell lines,
A549 and PC9, were obtained from the American Type Culture Collection (Rockville, MD,
USA). Cells were raised in DMEM medium, supplemented with 10% (v/v) FBS and 1% (w/v)
penicillin-streptomycin at 37°C with 5% (v/v)
CO2. The cells (5 × 103/well) were prepared into
a 96-well plate. After 24 h of incubation, the
cells were treated cordycepin for 48 h, after
which the cell viability assays were performed.
Briefly, at the end of the treatment, 10 μL of the
cell-counting kit-8 solution (Dojindo, Japan)
was added to the cells and incubated for 1
h at 36°C. Cell viability was determined by
measuring the absorbance at 450 nm using
a microplate reader (Sunrise, Tecan, Switzerland). The assays were performed in triplicates. Appropriate dose of cordycepin required
for treatment of A549 cell line was determined by evaluating the cytotoxicity of cordycepin for 48 h, followed by generation of micrographs of the treated cells.
Cell cycle analysis by PI-Annexin-V staining
Effect of cordycepin on apoptosis was analyzed using Annexin-V-FLUOS staining kit (Roche
Diagnostics) and observing the Annexin-V/propidium iodide (PI) staining patterns. The cells
were treated with cordycepin for 48 h, after
which they were scraped off and washed twice
with phosphate buffered saline (PBS). The cell
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suspension was centrifuged at 2000 rpm for
2 min and the pellet obtained was incubated
with 0.2 mg/mL Annexin-V FLUOS and 1.4 mg/
mL propidium iodide for 15 min at room temperature. This was followed by fluorescence
measurements in an Image Cytometer (NUCLEOCOUNTER® NC-3000™, Chemometec, Copenhagen, Denmark) at an excitation wavelength of 488 nm, with a 530/30 nm bandpass filter to detect Annexin-V and a 670-nm
high-pass filter to detect propidium iodide (PI).
Microarray analysis
Transcriptional profiling of the cordycepin-treated A549 cancer cells was carried out using a
human twin 44K cDNA chip. Total RNA was
extracted from vehicle or 60 μg/mL cordycepintreated A549 cancer cells. This was followed
by synthesis of cDNA probes using 50 mg RNA
in the presence of aminoallyl dUTP by reverse
transcription. The cDNA was coupled with Cy3
(vehicle) or Cy5 dye (cordycepin-treated). Genes
were considered to be differentially expressed when after a signiﬁcance analysis of the
microarray (SAM), the global M value, and log2
(R/G) exceeded |1.0| (twofold), with a p-value
< 0.05. A student’s t-test was applied to assess the statistical signiﬁcance of the differential expression of genes after cordycepin treatment. In order to analyze the biological signiﬁcance of the changes, the array data was categorized into speciﬁc gene groups.
Ontology-related network analysis
To study the biological role of ontology-related regulated genes and proteins through their
interaction networks, a bioinformatic network
analysis was conducted using the ingenuity
pathway analysis (IPA, http://www.ingenuity.
com). IPA identifies a gene interaction network
based on the regularly-updated “Ingenuity Pathways Knowledge-base”. The updatable database was retrieved from biological literature.
Network generation, aimed at the production
of highly-connected networks, was optimized
using the input expression profiles whenever
possible.
Western blot analysis
Expression profiles of cordycepin-treated apoptosis-related signaling proteins were examined
using western blotting. Denatured proteins (25
μg) was resolved on 12% polyacrylamide gel
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and transferred onto a nitrocellulose membrane. The nitrocellulose membrane was stained with Ponceau S to position the proteins.
The blotted membrane was blocked for 1 h
with 5% (w/v) skimmed milk in TTBS (Tween-20
and Tris-buffered saline), followed by incubation with a dilution of primary antibodies, ERK
(1:500), p-ERK (1:200), Bcl-2 (1:500), Slug (1:
500), caspase-3 (1:200), Bax (1:1000), PARP1 (1:1000), GSK3β, p-GSK3β and β-actin (1:
2000), at room temperature for 2 h or, alternatively, at 4°C overnight. After incubation,
the membrane was washed thrice with 0.1%
(v/v) Tween-20 in TBS for 5 min, followed by
incubation with horseradish-peroxidase (HRP)conjugated goat anti-mouse IgG or HRP-conjugated rabbit anti-goat IgG with a 1:2000
dilution in TBS containing 5% (w/v) skimmed
milk at room temperature for 1 h. The membranes were then washed thrice for 5 min
with TTBS, followed by visualization using an
enhanced chemiluminescence system (Thermo
Scientific, San Jose, CA, USA). The bands were
visualized on a ChemiDoc MP system (BioRad, Hercules, CA, USA). Densitometric measurements of bands were performed using
Image J software. Expression levels of proteins
were quantitatively analyzed through comparisons with actin as an internal control.
Biochemical analysis
For overexpression of ERK, lentivirus carrying
red fluorescent protein (RFP)-conjugated fulllength ERK1 (Lenti H1.4-ERK1/RFP; Bioneer
Corp., Daejeon, Korea) was used. Small interfering RNAs (siRNAs) were purchased from
Cell signaling and ST Pharm (Seoul, Korea).
The nucleotide sequence for Slug (GenBank
AF084243.1) siRNAs was 5’-AAG ATC TGA ACA
CAA GTG ACT-3’. A549 cells were seeded (2 ×
105 cells/6-well plates) on a microtiter plate.
After incubation, the cells were supplied with
growth medium containing 10% FBS and were
harvested after 48 h for further assays. The
transfection of siRNA into A549 cells was performed using lipofectamine RNAiMAX reagent
(Invitrogen, Carlsbad, CA, USA), according to
manufacturer’s instructions. After transfection, the cells were treated with cordycepin (60
μg/mL) for 48 h.
Determination of NO levels
NO levels were determined colorimetrically
using a NO detection kit based on the Griess
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method, which indirectly measures the concentration of NO by determining nitrite (NO2-)
concentrations. For the assay, 100 μL samples
were collected and added to wells in triplicates. This was followed by addition of 50 μL of
N1 buffer to the wells and incubation at room
temperature (RT) for 10 min. Afterwards, N2
buffer (50 μL) was added and the final reaction was carried out for 10 min at RT. Absorbance between 520-560 nm was measured
using an ELISA reader (Multiskan EX, Thermo
Lab systems, Beverly, MA, USA). Nitrite levels
were determined using a standard curve.
Measurements of cytokines
The levels of five different cytokines and chemokines interleukin 1 beta (IL-1β), IL-6, IL-8,
chemokine C-C motif ligand 5 (CCL5/RANTES),
and tumor necrosis factor-α (TNF-α) were measured in the growth medium supernatants of
A549 cells using a bead-based multianalyte
bead immunoassay (Invitrogen Cytokine human 25-plex panel, Cat No. LHC0009), according to the manufacturer’s protocol. Briefly,
diluted (1:2) culture supernatants were incubated with internally dyed polystyrene beads
coated with specific antibodies directed against one of the cytokines. Proteins present in
the culture supernatants bound to the antibody-coated beads during a 2 h incubation
period, after which the beads were washed
extensively. Biotinylated detector antibodies
directed against specific proteins were added
to the beads, where they bind to proteins derived from culture supernatants. After washing, streptavidin-conjugated R-phycoerythrin
was added to the bead-culture supernatant
derived protein-detector antibody complexes.
This was followed by washing of the unbound
streptavidin-conjugated R-phycoerythrin, and
analysis of the bead complexes using Luminex Detection system (Luminex® 200™ System, Thermo). Cytokine and chemokine concentrations in culture supernatants were extrapolated based on a standard curve generated using manufacturer-supplied standards
of each cytokine analyte.
Migration assay
The migration assay was conducted on control
and LPS, L-NAME, and cordycepin treated A549
cells. The cells were seeded onto a 24-well
plate. The monolayer was then scraped using a
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pipette tip to create a wound. The cells were
treated with cordycepin (100 μg/mL) for 48
h. The plates were visualized using the TissueFAXS system (TissueGontics, Vienna, Austria).
Cell migration was analyzed in terms of the
“healed” area migrated cells using the HistoQuest software (TissueGnostics, Vienna, Austria). The samples were analyzed using Zeiss
AxioImagerZ1 microscope system fitted with
a charge-coupled device camera and the TissueFAXSTM automated acquisition system (TissueGnostics, Vienna, Austria). The percentages
of antibody-positive and stemness marker-positive tumors were calculated and depicted as
scatter graphs. Images were digitalized and
protein expression was quantified. Statistical
flow analysis was performed using the HistoQuestTM software (TissueGnostics).
Immunofluorescence microscopy
A549 cells were seeded at a density of 4 × 104
cells/well on a coverslip in a 12-well plate. The
cells were pre-treated with cordycepin, LiCl,
and LPS with si-ERK for 24 h, followed by washing with 250 μM PBS (pH 7.5) twice and fixation with 4% (v/v) formaldehyde for 15 min.
The fixed cells were permeabilized using 0.1%
(v/v) Triton X-100 for 15 min and then incubated with 3% (w/v) bovine serum albumin
(BSA) for 1 h to prevent nonspecific binding.
Thereafter, the cells were incubated with the
primary antibody (Slug monoclonal purified
mouse IgG1 diluted to 1:100 in 3% (w/v) BSA)
overnight at 4°C, followed by 1 h incubation
with the secondary antibody [fluorescein isothiocyanate-anti-mouse antibody diluted to 1:
200 in 3% (w/v) BSA (Invitrogen Life Technologies, Carlsbad, CA, USA)] in dark. The coverslips were washed with PBS and mounted
with mounting solution for observation. Images
were acquired using an LSM 710 laser-scanning confocal microscope (Carl Zeiss, Jena,
Germany) at 488 nm Ar laser. Image data
were analyzed with ZEN 2009 Light Edition
software.
Statistical analyses
GraphPad Prism software (GraphPad, San
Diego, CA, USA) was used for the statistical
analyses. The student’s t-test was used to assess the statistical difference between control and the cordycepin-treated groups. P values less than 0.05 were considered as statistically significant.
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Figure 1. Viability and morphology of lung cancer cells after treatment with cordycepin. (A) Inhibition of the growth
of A549 and PC9 lung adenocarcinoma cells by cordycepin. Lung cancer cells were exposed to 0, 20, 40, 60, and
100 μg/mL cordycepin for 48 h. The data are presented as mean ± standard deviation from triplicate experiments.
Statistical significance was considered as **P < 0.01 vs. Non-treat control (B) Microscopic images of A549 cells
treated with cordycepin for 48 h. Magnification 400 ×. (C) Analysis of apoptosis of A549 cells exposed to cordycepin.

Results
Inhibition of growth in lung cancer cells by
cordycepin
Cordycepin was used directly to pretreat A549
and PC9 lung adenocarcinoma cells to examine
its effect on cell viability. Treatment with cordycepin gradually decreased the growth of both
the cell lines during 48 h of incubation (Figure
1). For the quantitative determination of 50%
inhibitory concentration (IC50) values, cordycepin was administered at 0, 20, 40, 60, 80, and
100 μg/mL for 48 h. At 60 μg/mL, cordycepin
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inhibited approximately 50% of the A549 and
PC9 cell populations. This value was, therefore,
taken as the IC50 of cordycepin. The cell morphology of A549 cell lines were observed in
order to assess the effect of cordycepin treatment on apoptosis (Figure 1B). Light microscopy revealed a change in the morphology of
A549 cells after treatment with cordycepin.
The cells began to detach from the surface
of the culture plate and appeared buoyant. A
change in shape from round to pointed polelike structure was also observed. These morphological changes preceded apoptosis. The
apoptotic effect of cordycepin on A549 lung
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Figure 2. Gene expression and signaling network analysis of ERK-Slug signaling-related genes. (A) Results of gene
ontology analysis by using microarray approaches. Gene lists corresponding to 2-fold up- and downregulation in
cordycepin-treated A549 cells for 48 h (B) Venn diagram of hierarchical clustering revealed genes that were altered
more than 2-folds upon apoptosis in response to cordycepin. (C) 35 gene lists (> 2-fold, < 2-fold, and apoptosis-related genes) are shown and are intersected individually by using Venn diagram. The red and green colors represent
more than two fold up- and downregulated genes, respectively. (D) Signaling network of the apoptosis-related genes
in response to cordycepin. Nodes colored by using a Qiagen IPA (red: upregulated genes, green: downregulated
genes).

cancer cells was analyzed using Annexin V and
PI staining by flow cytometry (Figure 1C). The
assay was performed to assess the induction
of apoptosis of cancer cells by cordycepin. For
the evaluation of apoptosis, the relative proportion of non-viable cells was quantitatively measured as the cells entered early stage of apoptosis (Annexin stained, non-disrupted cells) or
as the cells entered late stages of apoptosis
(disrupted or lysed cells). The flow cytometric
analyses of both the A549 cells was performed
and was compared before and after treatment
with 40, 60, and 80 μg/mL cordycepin for 48
h. Many Annexin V-stained viable A549 cells
shifted to the late apoptotic stage (2% to
31%). This suggests that cordycepin induced
the apoptotic process differently in lung cells.
Effect of cordycepin on gene expression profiles in lung cancer cell
To identify potential genes involved in the anticancer activity of cordycepin, microarray analysis was performed for A549 cancer cells after
treatment with cordycepin. Out of a total of
62,442 unique genes (using Agilent’s Human
GE 8x60K Microarray) analyzed, 28,812 genes
were expressed cells treated with 60 μg/mL
of cordycepin. Among these, 2,439 and 1,447
genes were up- and downregulated, respectively, by treatment with 60 μg/mL cordycepin compared to the untreated control after 48 h. The
genes that were up- or downregulated by more
than 2-folds were significantly handled in the
data mining categories. Biologically relevant
features were constructed using the Database
for Annotation, Visualization, and Integrated
Discovery (DAVID) tools (http://david.abcc.ncifcrf.gov/). Gene lists corresponding to 2-fold upor downregulation in the cordycepin-induced
lung cancer cells were uploaded to DAVID for
Gene Ontology analysis (Figure 2A). The upregulated genes were the ones involved in signal
transduction, immunity and defense, cell surface receptor mediated signaling, cell communication, apoptosis, ligand-mediated signaling,
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cell adhesion-mediated signaling, natural killer
cell mediated immunity, B-cell and antibodymediated immunity. Downregulated genes included those involved in transport, ion transport, cell adhesion, apoptosis, homeostasis,
and phosphate metabolism. To compare the
results obtained upon cordycepin treatment
with potential genes that are involved in apoptosis, we identified candidate 35 genes using
the GeneCards database (http://www.genecards.org/) (Figure 2B). The intersection obtained by hierarchical clustering is presented
along with the 35 gene lists in Figure 2C. The
signal network of apoptotic genes in response
to cordycepin is shown in Figure 2D. The hub
genes are MAPKs, NOS, ICAM1 (Intercellular
Adhesion Molecule 1), and TNF (tumor necrosis
factor).
ERK-Slug signaling linked apoptosis by cordycepin in A549 lung cancer cell
In various cell line models, apoptotic cell death
is induced by the serial activation of caspases.
To investigate whether cordycepin affects caspase activation to induce apoptosis, the expression profiles of p-ERK, ERK, Slug, Bcl-2,
Bax, caspase-3, cleaved caspase-3, PARP-1,
and cleaved PARP1 were observed by western
blot analysis of the A549 cell line (Figure 3).
The expression level of pro-apoptosis protein
Bax remained unchanged after the treatment
with 60 μg/mL cordycepin. On the other hand,
expression level of anti-apoptosis protein Bcl-2
was decreased and the expression of the active form of cleaved caspase-3 and cleaved
PARP-1 were significantly increased after treatment with cordycepin. These results corroborated the flow cytometric analysis (Figure 1C),
suggesting that A549 cells were sensitive to
cordycepin treatment and ultimately underwent apoptosis. Based on these data, effect
of cordycepin on the inhibition of ERK and Slug
pathways was assessed. The expression of pERK and Slug were clearly downregulated in
the presence of cordycepin.
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Figure 3. Protein expression post cordycepin treatment in lung cancer A549 cells. (A) Western blots showing the
expression of p-ERK, ERK, Slug, Bcl-2, Bax, caspase-3, cleaved caspase-3, PARP-1, and cleaved PARP-1, and (B)
relative band intensities in response to treatment with 0, 60 and 100 μg/ml of cordycepin in A549 cells. Data are
expressed as means ± SD, **P < 0.01, ***P < 0.001.

Cordycepin-induced reduction in NO production by inhibition of NOS and LPS-induced cytokine expression
To verify whether the inhibition of NO production by cordycepin was the mechanism underlying apoptosis, the levels of NO in the cell supernatants of various treatment groups were analyzed (Figure 4A). L-NAME is a well-known inhibitor of NOS and, therefore, inhibits NO production. A549 cells were treated with L-NAME
(500 μM) for 24 h, leading to the inhibition
of NO production, as compared to the non-LNAME-treated control cells. Further, the cells
were treated with L-NAME along with an excess of LPS (10 μg/mL) for 24 h. Presence
of LPS blocked the inhibition of NO production
by L-NAME. An increase in NO concentration
was observed of the cells as compared to
the untreated control. These data indicate that
endogenous NO plays a role in promoting cell
proliferation. The effect of LPS on the cordyce-
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pin-induced inhibition of NO production was
observed by treatment of A549 cells with cordycepin (60 μg/mL) for 24 h. In the absence
of LPS, production of NO was inhibited. Whereas, in the presence of LPS (10 μg/ml), its production was stimulated. Following this, levels
of NOS were assessed in the cordycepin-treated cells. Western blot analysis revealed that
treatment with cordycepin resulted in the inhibition of iNOS expression in LPS-stimulated A549 cells in a concentration-dependent
manner (Figure 4B, 4C). Cancer cells secrete
a number of cytokines, which mediate their
immune modulatory functions, and affect carcinogenesis, cancer cell proliferation, and metastasis. To investigate the correlation with NO
and cytokines in the inflammatory response,
levels of TNF-α, IL-1β, IL-6, IL-8, and CCL5 were
detected in A549 cells after treatment with
LPS (10 μg/ml) for 24 hours (Figure 4D). The
results obtained demonstrate that LPS mediates the upregulation in the expression and
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Figure 4. Effect of cordycepin on LPS-induced NO production and iNOS protein expression. (A) Effect of cordycepin
on NO production in LPS-stimulated A549 cells. Each column represents the mean ± SD of three independent experiments. ***P < 0.001. (B) Effect of cordycepin on LPS-induced iNOS protein expression, and (C) relative band
intensities of iNOS. (D) Effect of LPS on release of cytokines and chemokines in A549 cells. At the indicated time
points, cell supernatants were harvested and release of IL-1β, IL-6, IL-8, CCL5, and TNF-α was quantified by Human
Cytokine Twenty-Five-Plex. *Represents significantly different values from controls.

secretion of cytokines and chemokines, such
as TNF-α, CCL5, IL-1β, IL-6, and IL-8.
Inhibition of NO mediated ERK and Slug activation by cordycepin
Reduction in the levels of NO by L-NAME or
cordycepin resulted in a decrease in ERK phosphorylation, whereas the increase in the levels
of NO by LPS led to activation of ERK (Figure
5A and 5B). A significant reduction in LPS-induced ERK phosphorylation was observed in
the presence of cordycepin, suggesting that it
mediates the inhibition of ERK by downregulating the production of NO. A549 cells were
also treated with the specific NOS inhibitor
L-NAME (500 μM) for 6 h, which resulted in the
decrease in the basal concentration of p-ERK
and Slug in a dose dependent manner (Figure
5C and 5D). To evaluate the potential biological relevance of cordycepin, the effect of NO
on the migration of A549 tumor cells (Figure
5E) was assessed by a wound-healing assay.
Treatment of the cells with L-NAME (500 μM)
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for 24 h resulted in the inhibition of cell migration compared to non-L-NAME-treated control
cells. Further, the cells were treated with L-NAME in the presence of excess amount of LPS
for 24 h. Presence of LPS resulted in an increase in cell migration as compared to the cells
treated with L-NAME alone. These data indicate
that NO plays a crucial role in promoting the
migratory behavior of these cells. Thereafter,
the effect of LPS on the cordycepin-induced
inhibition of migration was analyzed. Treatment
of A549 cells with cordycepin (60 μg/mL) in
the presence of an excess amount of LPS (10
μg/ml) for 48 h recovered cell migration and
stimulated NO production, further suggesting
that the inhibition of cell migration by cordycepin is mediated by inhibition of ERK and Slug
activation mediated by NO.
Cordycepin downregulates ERK-Slug signaling
by inhibiting NO to induce Bax activation
To further investigate if ERK is functionally
linked to Slug signaling, the effect of cordyce-
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Figure 5. Inhibition of NO-mediated phosphorylation of ERK and the expression of
Slug by cordycepin (A) Effect of cordycepin on NO-mediated ERK phosphorylation and (B) relative band intensities of
p-ERK/ERK. Each column represents the
mean ± SD of three independent experiments. ***P < 0.001. (C) Inhibitory effect of L-NAME on ERK and Slug expression, and (D) relative band intensities of
p-ERK/ERK and Slug in a concentrationdependent manner as reflected from
the intensity of bands compared to nonL-NAME-treated controls. (E) Migration
assay of A549 cells. Cells treated with
L-NAME or their combinations with other
agents exhibited an extremely significant
inhibition of cell migration compared
with control cells. Data are expressed as
means ± SD, ***P < 0.001.
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Figure 6. Cordycepin mediated ERK/Slug signaling inhibition and Bax activation. (A) A549 cells were incubated
with siRNA directed against Slug (si-Slug) and transfected
with ERK-overexpression vector for 48 h, and (B) relative
band intensities of p-ERK/ERK, Slug, Bax, and cleaved
caspase-3. Data are expressed as means ± SD, ***P <
0.001. (C) GSK-3b phosphorylation regulates Slug (Snail2).
LiCl (50 µM) was used to treat A549 cells for 6 h, and (D)
relative band intensities of p-ERK/ERK, p-GSK3β/GSK3β,
and Slug. ***P < 0.001. (E) ERK upregulates Slug⁄Snail2
through GSK-3b inhibition. A549 cells were pretreated with
cordycepin for 6 h, and were incubated with siRNA directed
against ERK (si-ERK) or transfected with ERK-overexpression vector for 48 h, and (F) relative band intensities of pERK/ERK, p-GSK3β/GSK3β, and Slug. ***P < 0.001. (G)
Effect of ERK on Slug through GSK3β in A549 cells treated
with cordycepin. Effects of Slug nuclear and cytosol distribution under LPS with si-ERK, cordycepin, and LiCl were
observed by confocal microscopy. Representative analyses
are a result of at least four independent experiments.

427

Am J Cancer Res 2017;7(3):417-432

Apoptosis via nitric oxide mediated ERK/Slug signaling

Figure 7. Schematic diagram showing the mechanisms of action of cordycepin based on the findings of this study.
LPS-induced inflammatory microenvironment could stimulate the expression of TNF-α, CCL5, IL-1b, IL-6, IL-8 and
upregulate p-ERK and Slug. Cordycepin mediates Bax-induced apoptotic regulation of ERK/Slug through GSK3β
activation by downregulating NO production.

pin on ERK-Slug signaling was assessed (Figure 6). Downregulation of NO signaling was
obtained upon cordycepin treatment. Immunoblots confirmed the reduction in ERK and Slug
expression in A549 cell line. A loss-of-function
analysis using ERK knockdown by cordycepin
was performed. Cordycepin led to attenuation
of p-ERK and Slug expression, whereas ERK
overexpression upregulated p-ERK and Slug in
cordycepin-treated A549 cells. siRNA-mediated Slug inhibition enhanced the activation of
Bax and caspase-3 (Figure 6A, 6B), indicating
that cordycepin-mediated inactivation of ERK
downregulated Slug expression, leading to upregulation of Bax. In order to elucidate how
the upregulation of ERK enhances Slug activation, a comprehensive immunoblotting analysis of various signaling pathways in A549 cells
was performed. As a result, several alterations
were identified in the ERK/Slug signaling pathway (Figure 6). The presence of GSK3β inhibi-
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tor, LiCl (50 μM), alone increased the levels
of p-GSK3β and Slug (Figure 6C, 6D). On the
other hand, cordycepin mediated inhibition of
ERK in A549 cells treated with LPS resulted
in decreased levels of p-GSK3β and Slug. Besides, the silencing of ERK alone also resulted
in decreased p-GSK3β and Slug levels (Figure
6E, 6F). Consistent with this finding, nuclear
translocation of Slug was inhibited upon treatment with cordycepin alone and LPS with siERK, whereas increase in both cytosolic and
nuclear Slug under LiCl were observed by confocal microscopy (Figure 6G). These results indicate that ERK inhibition mediated by cordycepin downregulates the expression of Slug
through the activation of GSK3β.
Overall, these results suggest that cordycepinmediated inhibition of ERK downregulates Slug
signaling through the activation of GSK3β by
inhibiting NO, which upregulates Bax, and con-

Am J Cancer Res 2017;7(3):417-432

Apoptosis via nitric oxide mediated ERK/Slug signaling
sequently, induces apoptosis in the lung cancer
cell lines (Figure 7).
Discussion
Cordycepin possesses many important pharmacological properties, including inhibition of
inflammation, platelet aggregation, mRNA polyadenylation, and immunological stimulation.
In addition, it has remarkable anti-tumor effects, such as cell growth inhibition, induction
of apoptosis, and suppression of cell migration
and invasiveness [13, 16, 17]. The present
study demonstrated that treatment of A549
lung cancer cells with 60 μg/mL cordycepin
reduced their viability and led to a significant
growth reduction (Figure 1A). Moreover, treatment with 60 μg/mL cordycepin altered the
cell morphology of A549 cell line, as compared
to the untreated control and 40 μg/mL cordycepin-treated cells (Figure 1B, 1C). Annexin V/
PI staining of the cells using FACS demonstrated that cordycepin could induce pro-apoptosis.
Treatment with cordycepin at 60 μg/mL, but
not 40 μg/mL, induced the transformation of
cells from normal (untreated group: 91.0% normal, 4.0% early apoptotic, and 3% late apoptotic) to apoptotic state (65.0% normal, 26.0%
early apoptotic, and 8.0% late apoptotic) (Figure 1C). These results suggest that cordycepin
exhibits anti-lung cancer activity by promoting
pro-apoptosis.
Analysis of cordycepin-mediated alteration of
gene expression levels in lung cancer cells
was performed using microarray approach.
Clustering of the microarray data identified
groups of genes that were differentially regulated upon treatment of the A549 cells with 60
μg/mL of cordycepin. GO categories of genes
revealed the genes whose expression changed
by at least 2-folds (Figure 2A). Among these,
26 upregulated and 9 downregulated genes
were involved in apoptosis (Figure 2B and 2C).
To identify major cordycepin-regulated proteins
using GO analysis, IPA was used to query 33
proteins that were up- or downregulated by
cordycepin, yielding a distinct interconnected network of 27 proteins (Figure 2D). Among
these, downregulation of ERK/Slug was the
center of apoptosis-related protein network.
A549 cells were sensitive to treatment with
cordycepin, leading to bax-mediated apoptosis.
Cordycepin also inhibits the production of NO

429

by downregulation of iNOS and Cyclooxygenase-2 (COX-2) genes via the suppression of
NF-κB activation, Protein kinase B (Akt), and
p38 phosphorylation [18]. However, the role
of NO-ERK-Slug signaling in the induction of
apoptosis remains unclear. Although treatment
with L-NAME alone inhibited the production of
NO, the treatment in the presence of excess
amount of LPS restored NO production (Figure
4A). Thereafter, the effect of LPS on cordycepin-induced inhibition of NO production was
analyzed. Treatment of A549 cells with cordycepin in the presence of an excess amount
of LPS blocked LPS-stimulated production of
NO. Western blot analysis revealed that cordycepin-induced reduction in the production
NO is associated with an inhibitory effect of
cordycepin on NOS in A549 cells. The treatment of cordycepin resulted in the inhibition
of iNOS expression in LPS-stimulated A549
cells (Figure 4B and 4C). These observations
suggest that cordycepin inhibits the production of NO by inhibiting NOS in A549 cells.
Several inflammatory cytokines and chemokines, such as TNF-α, IL-6, TGF-β, and IL-10,
have been observed to engage in the initiation,
promotion and progression of cancer [20] and
are potent inducers of a number of different
genes, such as NF-kappaB (NF-κB), p38, signal
transducer and activator of transcription 1
(STAT1), and iNOS [19]. LPS stimulates the
expression of proinflammatory cytokines and
chemokines in classical immune tissues as
well as in the skeletal muscle [20]. In this study,
LPS-mediated upregulation of the expression
and secretion of cytokines and chemokines,
such as IL-1β, IL-6, IL-8, CCL5, and TNF-α was
observed (Figure 4D). These findings indicate
towards the correlation between NO and cancer progression upon induction of inflammatory
response.
In the present study, the involvement of
NO/ERK/Slug signaling pathway in mediating
apoptosis in A549 cell line after cordycepin
treatment was observed. First, it was found
that cordycepin mediated downregulation of
ERK phosphorylation by inhibiting the production of NO production, which preceded apoptosis in A549 lung cancer cells. Second, downregulation of p-ERK reduced the expression
of Slug protein. Third, cordycepin-mediated inhibition of ERK downregulated the expression
of Slug proteins through the activation of GS-
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K3β. Finally, siRNA-mediated inhibition of Slug
led to upregulation of the levels of pro-apoptotic proteins, such as Bax and cleaved caspase-3.
Previous studies have identified NO as a molecule of interest in carcinogenesis and tumor
growth progression. However, there is a considerable controversy, confusion, and debate in
understanding its role in tumor biology. It is
said to have both, tumoricidal as well as cancer-promoting effects, which rely on its timing,
location, and concentration of exposure. NO
has been suggested to modulate different cancer-related events, such as angiogenesis, apoptosis, cell cycle, invasion, and metastasis [1].
Previous studies have shown that as the NO
levels decrease, a reduction of ERK phosphorylation occurs. On the contrary, increase in NO
levels also stimulates ERK activation [21, 22].
NO inhibits the phosphorylation of ERK and
promotes cancer cells apoptosis [23]. A reduction in the level of NO by L-NAME and cordycepin led to a decrease in ERK phosphorylation,
whereas increase in the levels of NO by LPS
resulted in activation of ERK (Figure 5A and
5B). Cordycepin significantly decreased LPS-induced ERK phosphorylation (Figure 5A), suggesting that ERK activation is inhibited by inhibition of NO production. A549 cells were also
treated with specific NOS inhibitor, L-NAME, at
the basal concentration of p-ERK. A dose-dependent reduction in Slug expression was observed (Figure 5C and 5D), further suggesting
that cordycepin inhibits NO-mediated ERK and
Slug activation.
Slug is regulated by the ERK-Fos-related antigen 1 (Fra-1)/c-Jun signaling axis through the
Activator protein 1 (AP1) consensus sequence
in the Slug promoter. ERK signaling pathway
also facilitates breast cancer cell migration by
regulating Slug expression [24]. Slug (SNAI2,
Snail2) induces the epithelial mesenchymal
transition (EMT) in physiological as well as in
pathological contexts. It is implicated in the
development and progression of lung cancer
[25, 26]. Knockdown of Slug significantly suppressed lung cancer cell proliferation. Furthermore, knockdown of Slug significantly inhibited
lung cancer cell invasion and metastasis [27].
We found that cordycepin attenuated p-ERK
and Slug, whereas ERK overexpression up-regulated p-ERK and Slug in cordycepin treated
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A549 cells (Figure 6A and 6B), indicating that
cordycepin-mediated ERK inactivation downregulated the Slug. Also we found siRNA mediated Slug inhibition blocked Slug and enhanced Bax and caspase-3 activation, suggesting that cordycepin-mediated ERK inactivation
down-regulated the Slug, leading to the up-regulation of Bax.
Further, effect of ERK induced phosphorylation of GSK3β on cordycepin-mediated inactivation of GSK3β and upregulation of Slug was
investigated. In previous studies, it has been
demonstrated that ERK associates with and
primes GSK3β for its inactivation [28], and that
functional regulation of Slug/Snail2 is dependent on GSK3β-mediated phosphorylation [29].
GSK3β regulates EMT and cancer metastasis
by degradation of Slug [30]. In the present
study, treatment with GSK3β inhibitor LiCl (50
μM) alone increased p-GSK3β and Slug levels
(Figure 6C and 6D), whereas cordycepin-mediated inhibition of ERK in A549 cells treated
with LPS resulted in decreased p-GSK3β and
Slug levels (Figure 6E and 6F). These results
indicate that cordycepin-mediated inhibition of
ERK downregulates Slug expression through
the activation of GSK3β.
In conclusion, it was demonstrated that the
levels of Bax protein were dramatically increased by the negative regulation of NO-mediated
ERK/Slug expression through the activation
of GSK3β in cordycepin-treated A549 cells.
These findings provide novel insights into the
molecular mechanisms of apoptosis in A549
cell line. Controlling NO expression may, therefore, provide new approaches and strategies
to promote apoptosis of A549 cells. Taken together, these results indicate that cordycepin
mediates apoptotic regulation of ERK/Slug by
Bax through the activation of GSK3β by downregulating NO. The study also highlighted a
potential therapeutic use of cordycepin in the
treatment of lung cancer.
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